Drug Makers Expedite Switch OTC Development, Sales After Japan Law Revision
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japanese drug makers are stepping up development and sales of switch OTC drugs with the hope of gaining market share, a continuing ripple effect from the recent amendment on OTC pharmaceuticals
You may also be interested in...
UnitedHealth Group's i3 announces "Phase I" Business Expansion In Japan
TOKYO - After two years of plotting an entry into the Japanese healthcare market, i3 Japan LLC, a fully owned subsidiary of UnitedHealth Group, announced July 1 it would start offering its services actively in the clinical development and National Health Insurance areas as part of a "Phase I business expansion"
UnitedHealth Group's i3 announces "Phase I" Business Expansion In Japan
TOKYO - After two years of plotting an entry into the Japanese healthcare market, i3 Japan LLC, a fully owned subsidiary of UnitedHealth Group, announced July 1 it would start offering its services actively in the clinical development and National Health Insurance areas as part of a "Phase I business expansion"
MHLW Introduces Tougher Sales Requirements For OTC Drugs
TOKYO - Japan's Ministry of Health, Labor and Welfare enacted re-amended regulations of the Pharmaceutical Administration Law, effective June 1, which in principle require over-the-counter pharmaceutical sales in face-to-face transactions between pharmacists and registered salespersons and consumers but set a two-year grace period for distribution via the Internet and mail order and to remote, sparsely populated areas